Zero Ischemia Robot-Assisted MWA Assisted Suture-less Tumor Enucleation of RCC With T1 Stage
ConditionKidney Neoplasms
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age15-80
SponsorRenJi Hospital
About this trial
Zero ischemia laparoscopic radio frequency ablation assisted tumor enucleation has been proved to enable tumor excision with relatively better renal function preservation comparing with conventional laparoscopic partial nephrectomy for T1a renal cell carcinoma (RCC) in a randomized clinical trial in single center. The investigators want to explore this technique to robotic surgery and add suture-less technique to T1 RCC patients in randomized clinical trial.
Eligibility criteria
Qualifiers
patients with sporadic, unilateral, newly diagnosed T1 presumed renal cell carcinoma
patients scheduled for robot-assisted laparoscopic nephron sparing surgery
patients with normal contralateral renal function (differential renal function of >40% as determined by radionuclide scintigraphy)
patients agreeable to participate in this long-term follow-up study
Disqualifiers
patients' age >80 years
patients with other renal diseases (including kidney stone, glomerular nephritis, etc.)which might affect the renal function of the operative kidney
patients not able to tolerate the robot-assisted laparoscopic procedure
patients with previous renal surgery or history of any inflammatory conditions of the operative kidney
Trial design
Treatments tested in this trial
- Zero Ischemia Robot-Assisted Laparoscopic Microwave Ablation Assisted suture-less Enucleation
- robotic-assisted laparoscopic partial nephrectomy
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov